Drug Profile
Meningococcal vaccine groups A C Y W-135 conjugate (second generation) - Sanofi
Alternative Names: Men Quad TT; MenACYW conjugate vaccine; Meninge ACTW conj - Sanofi; Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine; MenQuadfi; Quadrivalent Meningococcal Conjugate Vaccine; TetraMen-TLatest Information Update: 06 Mar 2024
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Conjugate vaccines; Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Meningococcal group A infections
- Registered Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
Most Recent Events
- 06 Mar 2024 Sanofi plans a phase III trial for Meningococcal infections (Prevention, In infants) (IM, Injection) in March 2024 (NCT06284915) (EudraCT2023-508177-85)
- 18 Jan 2024 Phase-III clinical trials in Meningococcal group A infections (In children, In adults, In the elderly, Prevention, In adolescents, In infants) in Vietnam (IM) (NCT06228586)
- 18 Jan 2024 Phase-III clinical trials in Meningococcal group C infections (In children, In adults, In the elderly, Prevention, In adolescents, In infants) in Vietnam (IM) (NCT06228586)